Synthesis of sulfonylurea conjugated copolymer via PEO spacer and its in vitro short-term bioactivity in insulin secretion from islets of Langerhans

Biomaterials

Volumn 19, Issue 13, 1998, Pages 1189-1195

  Hwang, Jun Seok ^a   Chae, Su Young ^a   Lee, Moon Kyu ^b   Bae, You Han ^a  

^a Gwangju Institute of Science and Technology (GIST)   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Biohybrid artificial pancreas; Insulin secretion; Islet of Langerhans; Poly(N vinyl 2 pyrrolidone co sulfonylurea succinyl PEO acrylate) Water soluble polymer

Indexed keywords

ANIMAL CELL CULTURE; BIOSYNTHESIS; GLUCOSE; GRAFT COPOLYMERS; INSULIN; PH EFFECTS; POLYETHYLENE OXIDES; SOLUBILITY; SULFUR COMPOUNDS; VINYL RESINS;

BIOACTIVITY; LANGERHANS ISLET; SULFONYLUREA;

ARTIFICIAL ORGANS;

ACRYLIC ACID DERIVATIVE; CELL RECEPTOR; COPOLYMER; GLIBENCLAMIDE; GLUCOSE; INSULIN; POVIDONE; SULFONYLUREA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG SYNTHESIS; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PH; PRIORITY JOURNAL; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOCOMPATIBLE MATERIALS; CELLS, CULTURED; GLYBURIDE; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MOLECULAR WEIGHT; PANCREAS, ARTIFICIAL; POLYETHYLENE GLYCOLS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; SOLUBILITY;

ANIMALIA;

EID: 0032104252     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(98)00008-8     Document Type: Article

References (24)

1. [1] Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med 1942;21-22:441-4.
2. [2] Janbon M, Lazerges P, Metropolitanski JH. Etude du Métabolisme du sulfaisopropyl-thiodiazol (VK 57 ou 2254 RP) Chea le sujet sain et en cours de traitement. Comportement de la glycémie. Montpellier Med 1942;21-22:489-90.
3. 2-n-butylcarbamid als perorales Antidiabetikum. Dtsch Med Wochenschr 1956;81:750-1.
4. + channel in mouse pancreatic β cells by their combined actions at inhibitory and stimulatory receptors. Mol Pharmacol 1992;41: 480-6.
5. [5] Pfeifer MA, Halter JB, Beard JC, Porte D. Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1982; 54:95-100.
6. [6] Mikos AG, Papadaki MG, Kouvrouloglou S, Ishaug SL, Thomson RC. Mini review: islet transplantation to create a bioartificial pancreas. Biotechnol Bioeng 1994;43:673-7.
7. [7] Bailey GJ, Biguanides and NIDDM. Diabetes Care 1992;15: 755-72.
8. [8] Goberna R, Fussganger RD, Raptis S, Ditschune H, Pfeiffer EF. Glybenclamid (HB 419) and the prediabetes of subtotally pancreatectomized rats. Horm Metab Res 1969;1:175-7.
9. [9] Boyd III AE. Sulfonylurea receptors, ion channels, and fruit files. Diabetes 1988;37:847-50.
10. [10] Panten U, Schwanstecher M, Schwanstecher C. Pancreatic and extrapancreatic sulfonylurea receptors. Horm Metab Res 1992;24: 549-54.
11. [11] Zunkler BJ, Trube G, Panten U. How do sulfonylureas approach their receptor in the β-cell plasma membrane? Naunyn-Schmiedeberg's Arch Pharmacol 1989;340:328-32.
12. [12] Nelson TY, Gaines KL, Rajan AS, Berg M, Boyd III AE. Increased cytosolic calcium: a signal for sulfonylurea-stimulated insulin release from beta cells. J Biol Chem 1987;262:2608-12.
13. [13] Grous FK, Schuit FC, IN'T Veld PA, Gepts W, Pipeleers DG. Interaction of sulfonylureas with pancreatic β-cells: a study with glyburide. Diabetes 1988;37:1091-5.
14. [14] Panten U, Burgfeld J, Goerke F, Pennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic inlets. Biochem Pharmacol 1989;38:1217-29.
15. [15] Gaines KL, Hamilton S, Boyd III AE. Characterization of the sulfonylurea receptor on beta cell membranes. J Biol Chem 1988;263:2589-92.
16. [16] Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15: 737-54.
17. [17] Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993;16: 1254-61.
18. [18] Obereigner B, Buresova M, Vrana A, Kopeček J. Preparation of polymerizable derivatives of N-(4-aminobenzenesulfonyl)-N'-butylurea. J Polym Sci 1979;66:41-52.
19. [19] Kikuchi A, Bae YH, Kim SW. Stimulatory effect of a sulfonylurea analogue and its polymer conjugate on insulin secretion from rat islets. Biotechnol Prog 1994;10:630-5.
20. [20] Lacy PE, Kostianousky M. Method for the isolation of intact islets of Langerhans form the rat pancreas. Diabetes 1967;16: 35-9.
21. [21] Ramírez CA, López M, Stephens CL. In vitro perfusion of hybrid artificial pancreas devices at low flow rates. ASAIO J 1992;38: M443-9.
22. [22] Lévesque L, Burbaker PL, Sun AM. Maintenance of long-term secretory function by microencapsulated islets of Langerhans. Endocrinology 1992;130:644-50.
23. [23] Feil H, Bae YH, Feijen Y, Kim SW. Effect of comonomer hydrophilicity and ionization on the lower critical solution temperature of N-isopropylacrylamide copolymers, Macromolecules 1993;26: 2496-500.
24. [24] Harris JM. Poly(ethylene glycol) chemistry, biotechnical and biomedical applications. New York: Plenum Press, 1992.